Core Viewpoint - China Biologic Products (01177) announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has initiated a Phase III registration clinical trial for its innovative drug, LM-302, targeting CLDN18.2 positive advanced gastric and gastroesophageal junction adenocarcinoma, marking it as the first CLDN18.2 ADC drug to complete patient enrollment in a Phase III trial [1][2]. Group 1 - LM-302 is an antibody-drug conjugate (ADC) that specifically targets CLDN18.2 positive tumor cells, delivering a small molecule toxin to achieve precise tumor cell destruction [1]. - The drug shows promising clinical development potential in various gastrointestinal tumors, including gastric cancer, pancreatic cancer, and cholangiocarcinoma, and aims to provide new treatment options for patients with low CLDN18.2 and PD-L1 expression [1][2]. - At the 2025 ASCO annual meeting, Lixin Pharmaceutical reported an objective response rate (ORR) of 65.9% and a disease control rate (DCR) of 85.4% in 41 evaluable patients, with even higher rates in patients with CLDN18.2 expression ≥25% [2]. Group 2 - In addition to the ongoing Phase III study for advanced gastric cancer, LM-302 is set to undergo another Phase III trial in China, combining it with PD-1 monoclonal antibodies for first-line treatment of CLDN18.2 positive advanced gastric cancer [2]. - Multiple indications for LM-302 have been designated as breakthrough therapies by the China National Medical Products Administration (NMPA) and have received orphan drug designation from the U.S. FDA [2]. - Lixin Pharmaceutical is accelerating the clinical transformation and commercialization of more innovative drugs, aiming to provide accessible treatment options for global cancer patients [3].

Core Viewpoint - The company has presented additional follow-up data for IBI363 and IBI343 at the ASCO conference, showing promising results that enhance confidence in their development, leading to an upward revision of the target price to HKD 95 and a reaffirmation of the "buy" recommendation [1][5]. Group 1: IBI363 Data Insights - The mPFS for the IBI363 3mg/kg dose group in IO-treated sq-NSCLC has been extended to 9.3 months, an improvement from the previously reported 7.3 months, indicating strong efficacy [2][3]. - In the EGFR wild-type adenocarcinoma (EGFRwt Ad-NSCLC), the mPFS remains consistent at 4.2 months, outperforming docetaxel's mPFS of 2.5-4 months [2]. - The company plans to initiate a Phase III registration clinical trial for IBI363 in 3L+ sq-NSCLC, with the 3mg/kg dose expected to be used [2]. Group 2: IBI343 and Other Data - IBI363 combined with bevacizumab shows a 15.1% cORR and a 4.7-month mPFS, with a notable 31.3% cORR and 7.4-month mPFS in the population without liver metastasis [3]. - The overall mOS for IBI363 monotherapy is reported at 16.1 months, with subgroup analysis showing mOS of 14.4 months for liver metastasis patients and 17.0 months for those without, both significantly higher than the 9.3 months for fruquintinib in 3L CRC [3]. - In melanoma, the IBI363 1mg/kg Q2W dose group shows mPFS of 5.7 months and mOS of 14.8 months, significantly better than real-world data [4]. Group 3: Financial Projections - The company forecasts peak sales of approximately HKD 2.5 billion for IBI363 and HKD 1.5 billion for IBI343 in China, adjusted for risk [5]. - Projected net profits for the company are estimated at HKD 430 million, HKD 850 million, and HKD 1.89 billion for the years 2025, 2026, and 2027, respectively [5].